Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Why Pure-Play Healthcare Technology Innovation Matters

BY | ETF Database
10:20 am ET 07/06/26 | 9 VIEWS
Portfolios are commonly underexposed to the companies driving healthcare innovation. As technological disruptions build across medical fields, the ROBO Global Healthcare Technology and Innovation ETF (HTEC B) provides targeted exposure to the global value chain driving this high-growth opportunity.Key Takeaways Traditional cap-weighted healthcare funds leave portfolios heavily exposed to legacy pharma while missing specialized medical technology. High-performing diagnostic and genomic businesses led HTEC’s underlying index performance during the first half of 2026. Broadening a portfolio into specialized clinical tech allows advisors to capture early-stage medical breakthroughs without added tech sector overlap. Breaking Down the HTEC Performance DriversHTEC targets nine distinct healthcare categories, including precision medicine, medical instruments, genomics, process automation, diagnostics, robotics, regenerative medicine, telehealth, and data analytics.  The underlying index, the ROBO Global Healthcare Technology and Innovation Index (HTEC), captured strong gains from several high-growth companies year to date through July 3. Genomics specialist Twist Bioscience Corporation (TWST) led the index by portfolio attribution, climbing 212.9% and contributing 2.8% to total index performance over the timeframe. Moderna Inc (MRNA) also saw significant momentum during the period, posting a 170.5% return and providing a 1.9% performance contribution to the index. Now is an ideal time to gain exposure, as this momentum reflects a broader operational shift across the wider market. Smaller medical tool developers and liquid biopsy innovators are playing a completely different game than pharma giants. Guardant Health (GH) serves as an example of the high-growth potential of the industry. The stock surged 64.5% year to date through July 3, driving a 1.4% contribution to the HTEC index. Investors can look at investment opportunities beyond big tech to potentially diversify portfolios and enhance performance. Adding focused exposure on specialized healthcare platforms avoids overlapping with standard broader market ETFs. Ultimately, evaluating the fundamental strengths of companies redefining healthcare offers a clearer pathway for a long-term thematic allocation. For more news, information, and analysis, visit the Thematic Investing Content Hub. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for HTEC, for which it receives an index licensing fee. However, HTEC is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC.

More Commentary

Dimensional Expands Share Class Push Into Fixed Income
BY | ETF Database
7:54 am ET 07/06/26 | 13 VIEWS
June Tech Flows Could Create More Investing Opportunities
BY | ETF Database
8:36 am ET 07/06/26 | 17 VIEWS
The Defined Outcome Advantage: Buffer ETFs' Performance in 2026
BY | ETF Database
7:50 am ET 07/06/26 | 27 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.